Ophthalmology 360?

Both low-level light therapy (LLLT) and intense pulsed light (IPL) therapy are effective in treating Meibomian gland-related dry eye, but IPL may better improve symptoms and tear film stability compared to LLLT, according to a study. Read the complete article below ?? https://lnkd.in/eY9EBmaR #DryEyeDisease #DryEye #OcularSurfaceDisease

This month, our Spotlight Series features a look at XEN? Gel Stent, a minimally invasive bleb surgery device that is used for patients with glaucoma. Learn about the safety and efficacy data for XEN? Gel Stent ?? https://lnkd.in/eWFAN967 #Glaucoma #MIGS #IntraocularPressure AbbVie

It’s a huge responsibility Speaking for others - in addition to myself. Last week I was in D,C. Not only telling my story - but the story of so many other glaucoma patients as well. The challenges, the fears, and the small wins. It a huge responsibility to be the voice of so many and one I don’t take lightly. A path that has chosen me. A fight that is so much bigger than me. A higher purpose that drives me. The patient. Always - Start with the Patient!

?? Alcon announced a definitive agreement to acquire LENSAR, Inc., strengthening its position in femtosecond laser-assisted #cataract surgery. Read more ?? https://lnkd.in/ejwVMNRh

A recent retrospective analysis examined the association between diabetes mellitus, neurotrophic keratopathy, and corneal ulcers. The study reviewed 136,992 health records from patients visiting a university outpatient clinic between January 2003 and February 2024. Read the complete article below ?? https://lnkd.in/ef5viPEB #NeurotrophicKeratitis #Diabetes #Cornea

"Successful enrollment in ophthalmic clinical trials hinges on strategic planning, robust partnerships, and meticulous execution. By leveraging data-driven insights, fostering strong relationships with clinical sites, and selecting experienced investigators, sponsors can enhance recruitment and retention, ensuring efficient trial completion." Read the complete article by Yesha Raval, MS, and Andrew D. Pucker, OD, PhD, FAAO Diplomate, FSLS, FBCLA ?? #Ophthalmology360 #ClinicalTrials #Ophthalmic #MedicalPractice #MacularDegeneration #Glaucoma

"Dry eye disease (DED) is a common condition encountered in clinical practice, yet its underlying pathophysiology remains complex and multifactorial. The ocular surface comprises various structures that work in harmony to maintain homeostasis. Disruption of any one of these components can lead to a breakdown in this balance, resulting in the vicious cycle of DED." Read the complete article written by Cory Lappin, OD, MS, FAAO, and Matthew Shulman, MD ?? https://lnkd.in/e7yKx9mx #DryEyeDisease #DryEye #OcularSurfaceDisease

Dextenza, a sustained-release dexamethasone insert, is an effective and convenient option for reducing postoperative inflammation in pediatric intraocular surgery, minimizing the need for frequent eye drops and improving treatment compliance, according to a paper presented at the 50th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus. Read the complete article below ?? https://lnkd.in/e8vSZmxt #Cataracts #PediatricOphthalmology #CataractSurgery

Gene therapy is emerging as a promising treatment for genetic retinal disorders, with research demonstrating significant progress in animal models and early clinical trials, according to a presentation at the 50th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus. Read more: https://lnkd.in/ezgyrpVp #EarlyOnsetCataracts #Cataracts #GeneTherapy #Genetics

Incredible day on the Hill yesterday with National Alliance for Eye and Vision Research (NAEVR) and Thomas V Johnson! We spoke about glaucoma from the perspective of the patient and clinician/researcher. Dr Johnson shared some of his incredible research on regrowing retinal ganglion cells. We also had the opportunity to meet with several Congressional offices to discuss the importance of continued funding for eye and vision research. Patients coupled with clinicians/researchers make magic happen. Separately we make a difference - together we create change!